Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Now, if ever there ...
In an interview with Targeted Oncology, Gerrina Ruiter, MD, PhD, Netherlands Cancer Institute and study investigator, ...
Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...
For patients with high-risk HER2-positive early breast cancer who have undergone neoadjuvant therapy, treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) significantly improved invasive ...
Claudine Isaacs, MD: For this patient who's progressed after more than 12 months with an ESR1 mutation and HER2-low disease ...
Tagworks Pharmaceuticals BV ("Tagworks"), a clinical-stage precision oncology company using its proprietary Click-to-Release ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Joining me today ...
The U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant) for the treatment of adults with estrogen ...
Hosted on MSN
A Promising New Option For PIK3CA-Mutated Breast Cancer: What New Data On Inavolisib Could Mean for You
Some breast cancers “feed” on the hormone estrogen. These are usually treated with medicines that either block estrogen’s signal (fulvestrant) or slow the cancer’s growth cycle (palbociclib). In about ...
Pfizer announces Tukysa combination significantly improves PFS as first-line maintenance in HER2+ metastatic breast cancer in HER2CLIMB-05 trial: New York Wednesday, October 15, 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback